Table 1.
Included studies and their characteristics.
| Author, Year | Country | n | % Male | Me(di)an Age (SD, Range or Percentage Older) | Type of Cancer | Treatment Setting |
|---|---|---|---|---|---|---|
| Pieterse [25], 2007 | NL | 66 | 68% | 64 (±9) | Gastrointestinal | Curative |
| Mohamed [26] 2011 | USA | 138 | 49% | 57 (±9) | Renal cell | Curative |
| Thrumurthy [27] 2011 | UK | 81 | 77% | 67 (38% > 70) | Esophageal | Curative |
| * Jorgensen [28], 2013 | Australia | 68 | 100% | 64 (51% > 65) | Colorectal | Curative |
| Molinari [29], 2014 | Canada | 75 | 61% | 51 (±11) | HCC | Curative |
| Thill [16], 2016 | Germany | 41 | 100% | 50 (29–76) | Breast | Curative |
| van der Valk [30] 2020 | NL | 94 | 43% | 62 (±9) | Rectal | Curative |
| Werner [31], 2021 | Germany | 37 | 51% | 59 (±9) | Anal/colorectal | Curative |
| Park [32], 2012 | Korea | 140 | 37% | 57 | Renal cell | Palliative |
| Havrilesky [33], 2014 | USA | 95 | 0% | 60 (±10) | Ovarian | Palliative |
| DaCosta [34], 2014 | USA | 181 | 0% | 52 (±9) | Breast | Palliative |
| Muhlbacher [35], 2015 | Germany | 211 | 65% | 59 (±8) | NSCLC | Palliative |
| * Uemura [36], 2016 | Japan | 133 | 100% | 75 (±7) | Prostate | Palliative |
| * Chau [37], 2016 | Canada | 36 | 100% | 73 | Prostate | Palliative |
| Gonzalez [38], 2017 | USA | 127 | 54% | 46 (±16) | Colorectal | Palliative |
| Liu [39], 2019 | USA | 200 | 40% | 34% >50 | Melanoma | Palliative |
| Wong [40], 2020 | Singapore | 169 | 58% | 62 (±11) | Colorectal | Palliative |
| * Stegmann [41], 2020 | NL | 53 | 72% | 75 (±7) | Various types | Palliative |
| Weilandt [42], 2021 | Germany | 150 | 60% | 59 (23–85) | Melanoma | Both |
| Johnson [43], 2006 | USA | 375 | 30% | 61 (±12) | Various types | Both |
| Schmidt [44], 2017 | Germany | 310 | 62% | 63 (±11) | Various types | Both |
| Sun [45], 2019 | China | 361 | 63% | 58 (31–82) | NSCLC | Both |
| Bröckelmann [46], 2019 | EU | 289 | 64% | 36 (19–75) | Lymphoma | Both |
| * Festen [47], 2019 | NL | 197 | 56% | 78 (70–93) | Various types | Both |
| Valenti [48], 2020 | Spain | 100 | 51% | 64 (29–85) | Various types | Both |
| Fifer [49], 2020 | UK | 419 | 44% | 93% >50 | MM | Both |
| * Festen [50], 2021 | NL | 87 | 52% | 76 (IQR 72–80) | Various types | Both |
| Khan [51], 2020 | USA | 141 | 50% | 35 (19–69) | Lymphoma | Both |
NSCLC (non-small cell lung cancer), HCC (hepatocellular carcinoma), MM (multiple myeloma), NL (the Netherlands), USA (United States of America), UK (United Kingdom), EU (European Union). * Studies with median age above 70 or separate data for this subgroup.